Immunotherapy / PD-1 inhibitorPhase 3 trialInvestigational
Avelumab
How it works
Blocks the action of a protein called programmed death-1 (PD-1), which is involved in the regulation of the immune system. This allows the immune system to recognize and attack cancer cells.
Cancer types
Efficacy
Studies are ongoing to evaluate the efficacy of avelumab in patients with ovarian cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Treatments for Advanced Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing Palbociclib and Avelumab in Metastatic Triple Negative Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| New Combination Treatment Shows Promise for Rare Neuroendocrine Tumors | Pancreatic Cancer | phase-2 | The 6-month objective response rate was 18% (95% confidence interval: 8-31%), with a median progression-free survival of 5.5 months (95% CI: 3.6-8). | Source → |
| Study Examines Combination Therapy for Advanced Breast Cancer | Breast Cancer | phase-2 | The median progression-free survival on F + P + A was 8.1 months (HR 0.75 [90% CI, 0.50 to 1.12]; = .23). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.